Editorial

                     


October 5, 2012

Avon’s Turn-around Story Closes a Another Chapter
Filed under: Cons. Discretionary,Equities Editor's Desk,Healthcare — Andrew Klips @ 9:45 am

As part of its transition to new leadership, Avon Products (AVP) said Friday that executive chairman and board of directors member Andrea Jung is stepping-down from her positions at the end of 2012. She will remain a part of the door-to-door cosmetics seller’s team in an advisory capacity.

Jung, 54, became the first woman CEO of Avon in 1999 and held that position until resigning last December. She is currently a member of the board for both GE (GE) and Apple (AAPL).

She was replaced as Avon chief executive by Johnson & Johnson executive Sherilyn S. McCoy in April. Fred Hassan, who joined Avon in 1999 and currently serves as lead independent director, will be become non-executive chairman of the board.

Hassan is presently a partner and managing director at private equity firm Warburg Pincus and previously was the Chief Executive Officer at Schering-Plough Corp. Merck & Co. (MRK) acquired Schering-Plough in 2009 in a $41.1 billion merger.

Avon is looking to be a turn-around story as it has been under tremendous pressure related to three straight years of declining profit, a rejected takeover attempt from Coty, Inc. and a federal probe for allegations of bribing foreign officials. With a background in marketing, not operations, Jung was perhaps not equipped with the tools to deal with the plethora of challenges. In August the company released earnings showing a 70 percent plummet in sales and tightening margins, citing lower demand globally for its makeup and skin-care products.

The market is apparently viewing the move as a step in the right direction for the company. Shares have been treading water around $16 for the four months, but have surged ahead to above $17 per share in morning trading. 

Comments

comments


About Andrew Klips

Andrew Klips became enraptured with the markets as a teenager and has been an active trader on a daily basis for more than a decade. Specializing in technical analysis, he is an avid player of stock charts making technical bottoms mixed with a particular affinity for the fundamentals of biotechnology companies. (read more about Andrew Klips)...
| |

Comments

No Comments »

RSS feed for comments on this post. TrackBack URL

Leave a comment

 

Sector News



Market Overview

Symbol Last Change % Change
DJIA15,387.5852.300.34
NASDAQ3,502.125.691530.16
S&P 500 EOD1,669.182.890.17
10yr Trsy19.44-0.26-1.32
Data is delayed 20 mins/EOD

Uncommon Wisdom with Fisher Investments

Fisher Investments
Japanese policymakers largely understand what their Chinese counterparts don’t—encouraging private firms to invest more and as they see fit is the best way to goad sustainable economic growth.

Behind the Frontlines with Mauldin Economics

John Mauldin
They aren't currency wars, they're currency tensions. -- Mohamed El-Erian. Either way, Japan is ruffling a lot of feathers as it exports deflation.

Richard Suttmeier of ValuEngine

Richard Suttmeier
The daily chart for MCP shows declining momentum with the stock above its 21-day and 50-day simple moving averages and below its 200-day simple moving average.